FLT3 and acute myeloid leukemia: This study focuses on transplant-ineligible, FLT3-ITD(+) AML patients in remission post-chemotherapy, evaluating the combination of sorafenib and the ITI regimen as maintenance therapy, with close monitoring of MRD dynamics and survival outcomes, aiming to provide novel clinical insights and therapeutic strategies.